Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

ABSTRACT:

SUBMITTER: Sklavenitis-Pistofidis R 

PROVIDER: S-EPMC6293872 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature